{"id":"W2767805413","doi":"10.1016/s1474-4422(17)30378-2","title":"Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Neurology","topic":"Peripheral Neuropathies and Disorders","field":"Medicine","cited_by":269,"is_retracted":false,"has_abstract":false,"ca_institutions":"University Health Network; University of Toronto","funders":"Sanofi Genzyme; Seventh Framework Programme; Genentech; Grifols; Ono Pharmaceutical; Mitsubishi Tanabe Pharma Corporation; Teijin Pharma; Prinses Beatrix Spierfonds; Ministry of Health, Labour and Welfare; Pfizer Japan; Shionogi; Argenx; Bayer Yakuhin; Celgene; Ministry of Education, Culture, Sports, Science and Technology; Calithera Biosciences; Union Chimique Belge; Neurocrine Biosciences; Kissei; Boehringer Ingelheim Japan; Teva Pharmaceutical Industries; Myasthenia Gravis Foundation of America; Bayer HealthCare; European Commission; Sanofi; Pfizer; Biogen; Japan Society for the Promotion of Science; GlaxoSmithKline; Bristol-Myers Squibb; CSL Behring; AstraZeneca; Eisai","keywords":"Medicine; Chronic inflammatory demyelinating polyneuropathy; Placebo; Internal medicine; Clinical trial; Polyradiculoneuropathy; Randomized controlled trial; Antibody; Polyneuropathy; Intention-to-treat analysis; Physical therapy; Surgery; Pediatrics; Guillain-Barre syndrome; Immunology; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001622489,0.001803231,0.004290544,0.0005728861,0.0004775694,0.001070362,0.001353162,0.002925986,0.008865932],"category_scores_gemma":[0.001484561,0.0005269477,0.002306661,0.0006356082,0.001541249,0.001394337,0.0004580253,0.003202592,0.001374497],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000775657,"about_ca_system_score_gemma":0.001027023,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00131589,"about_ca_topic_score_gemma":0.002128759,"domain_scores_codex":[0.9994873,0.0002123606,0.00003385401,0.0001031529,0.00004768893,0.0001157156],"domain_scores_gemma":[0.999217,0.0002860753,0.0001533215,0.0000627448,0.00005070743,0.0002301193],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9798737,0.002255689,0.0002109098,0.001152023,0.0007883685,0.00004418207,0.00003695146,0.0001494362,0.001374651,0.00008435976,0.0005634159,0.01346648],"study_design_scores_gemma":[0.9792013,0.01968521,0.0004973147,0.00003311838,0.0001584624,0.00001669114,0.000008126573,0.00008337982,0.0000672235,0.00005847406,0.0001855038,0.000005178462],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9660384,0.01965401,0.001636634,0.00100294,0.001383331,0.00543147,0.001621007,0.0003684652,0.002863722],"genre_scores_gemma":[0.9718675,0.009252864,0.002555086,0.001969318,0.0009530083,0.007014402,0.001488097,0.00004814884,0.004851676],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008865932,"threshold_uncertainty_score":0.02965945,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04185788049793177,"score_gpt":0.332183446972469,"score_spread":0.2903255664745372,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}